Rare flowers atop the patent cliff: Sanofi picks itself up
This article was originally published in Scrip
Nobody expected 2012 to be a great year for Sanofi: the global number two pharma company has had to grapple with the loss of market exclusivity in key markets for major brands including the blood thinners Lovenox (enoxaparin) and Plavix (clopidogrel), the antihypertensive Aprovel (irbesartan), the chemotherapeutic Taxotere (docetaxel) and most recently Eloxatin (oxaliplatin). However, the advent of generic competition to Eloxatin in the US in August marked the end of Sanofi's patent cliff for now. And it looks likely that actually, 2012 won't be quite as bad as was once feared.